Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched ceftazidime for injection, USP, a semisynthetic broad-spectrum, beta-lactam antibiotic. Sagent will offer ceftazidime in 1 and 2g single dose vials and 6g pharmacy bulk package vials. According to IMS data, 2007 sales of injectable amiodarone in the United States were approximately $45.7 million.
The details can be read here.
No comments:
Post a Comment